AngioDynamics, Inc.
ANGODrugs in Pipeline
2
Phase 3 Programs
1
Upcoming Catalysts
1
Next Catalyst
Oct 1, 2026
4wMarket Overview
Stock performance and key metrics
1 upcoming, 0 past
How ANGO's past catalysts played out
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
Modified FOLFIRINOX Regimen | Phase 3 | Stage III Pancreatic Cancer | - | - |
IP-001 | Phase 2 | Colorectal Cancer | - | - |
Source: CatalystAlert database (ClinicalTrials.gov, SEC EDGAR)
Full breakdown — the signals behind the verdict
Frequently asked questions
What is in AngioDynamics, Inc.'s drug pipeline?→
CatalystAlert tracks 2 drug candidates in AngioDynamics, Inc.'s (ANGO) pipeline across Phase 3, Phase 2. Its lead program is Modified FOLFIRINOX Regimen (Phase 3). Each drug's phase, indication and upcoming catalysts are listed on this page.
When is AngioDynamics, Inc.'s next FDA catalyst?→
AngioDynamics, Inc.'s (ANGO) next tracked catalyst is a Earnings expected October 1, 2026. See the catalyst timeline on this page for the full schedule of PDUFA dates, trial readouts and FDA events.
How do I track ANGO biotech catalysts?→
Add ANGO to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow AngioDynamics, Inc.'s live catalyst calendar, drug pipeline and clinical-trial timeline on this page — sourced from ClinicalTrials.gov, FDA and SEC filings.